Neogen Chemicals Q4 FY26 Earnings Call Transcript Released
Neogen Chemicals released its Q4 FY26 earnings call transcript. The company reported Q4 FY26 revenue of ₹247 crore (up 22% YoY) and PAT of ₹11 crore. FY26 revenue was ₹862 crore. Promoter group infused ₹161 crore for battery materials expansion. Dahej facility commissioning is expected by June 2026, Pakhajan by H1 FY27.
The announcement provides detailed financial results, strategic updates on battery materials expansion, and revised project timelines and costs, which are material information for investors.
The company reported strong year-on-year revenue and EBITDA growth for Q4 FY26 and FY26. The strategic progress in battery materials, including promoter funding and facility development, indicates positive future outlook.
Neogen Chemicals Limited has released the transcript of its Q4 FY26 Earnings Conference Call, which was held on May 18, 2026. The call detailed the company's financial performance and strategic developments.
During the quarter, Neogen Chemicals reported consolidated revenue of ₹247 crore, a 22% year-on-year increase, with EBITDA at ₹44 crore, up 21% year-on-year, maintaining an EBITDA margin of 17.8%. Profit after tax for the quarter was ₹11 crore. For the full fiscal year FY26, revenue stood at ₹862 crore, an 11% year-on-year growth, with EBITDA at ₹137 crore and PAT at ₹29 crore.
The company highlighted its strategic focus on battery materials, with the promoter group infusing ₹161 crore through a preferential allotment to support Neogen Ionics and other initiatives. The Dahej replacement facility construction is progressing, with commissioning targeted for June 2026. The Pakhajan greenfield site is on track for commercial manufacturing of electrolyte in H1 FY27 and electrolyte salts in H2 FY27.
Revised project timelines and capital outlays were discussed for battery materials. The Dahej Phase 1 project is budgeted at ₹428 crore with completion by February 2027, and Pakhajan Phase 2 has a revised cost of ₹1,367 crore, expected completion by March 2027. These revisions are due to design optimization and increased localization. The strategic partnership with Japan's Morita is progressing, with an expected equity contribution of $20 million in H1 FY27.
Neogen Chemicals is confident in achieving standalone revenues between ₹875 crore and ₹950 crore in FY27, excluding battery materials. The company also recommended a final dividend of ₹1 per equity share for FY26.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.